Melvyn Little

Synergistic Antitumor Effect of Bispecific CD19 × CD3 and CD19 × CD16 Diabodies in a Preclinical Model of Non-Hodgkin’s Lymphoma1

Gerhard Moldenhauer, M. Little, S. Kipriyanov, 2002, The Journal of Immunology.

Targeting Recombinant Antibodies to the Surface of Escherichia coli: Fusion to a Peptidoglycan Associated Lipoprotein

Stefan Dübel, M. Little, F. Breitling, 1991, Bio/Technology.

Anti-LRP/LR specific antibodies and shRNAs impede amyloid beta shedding in Alzheimer's disease

Marc S. Weinberg, M. Little, C. Penny, 2013, Scientific Reports.